Company Overview and News
MONROE TOWNSHIP, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- Ocean Power Technologies (Nasdaq:OPTT), a leader in innovative ocean energy solutions today announced financial results for the fourth quarter and full fiscal year 2018 ended April 30, 2018.
PMOIF PMO PMOIY OPTT
Dril-Quip, Inc’s (DRQ - Free Report) wholly-owned subsidiary, Dril-Quip (Europe) Limited, has received a contract from Premier Oil Exploration and Production Limited to supply subsea production systems for its project offshore the Falkland Islands. A letter of intent has been inked by Dril-Quip with Premier Oil Exploration and Production Limited for the Sea Lion Phase 1 Development. Per the agreement, Dril-Quip will provide 23 subsea production systems comprising wellheads, trees, control systems, related production and injection manifolds, subsea umbilicals along with associated services.
DO DRQ POOL GTT PMOIF RKH OXY PMO PMOIY RCKHF
Bookies were among the few in London cheering England’s World Cup semi-final defeat after escaping a potential £100m hit if Gareth Southgate’s team managed to bring football home.
WIMHF RDS.B RDS.A PMOIF RDSB RDSA PMO WMH WIMHY RYDBF TLW RYDAF PMOIY
July 12 (Reuters) - Britain’s FTSE 100 index is to open 26 points higher at 7,618 on Thursday, according to financial bookmakers, with futures up 0.28 percent ahead of the cash market open.
FOX BLT NG CCV BHPBF CMCSA PMOIF CCZ PMO DFS BHP CCV.CL NGGTF BBL BHP BHPLF PMOIY FOXA CMCSK NGG
Spirit Energy Limited announced Friday that it has reached an agreement with its joint venture partners in the Babbage field to take on operatorship of the license, where it holds a 13 percent interest.
PMOIF PMO PMOIY
The company is positioned to deliver healthy production growth in FY18-FY20 and for the same period, EBITDA margin is likely to improve as well.
HES.PRA APC APA TALO HES SGY WTI PMOIF MRO PMO PMOIY EOG
Sapura Energy Bhd (July 2, 62 sen) Maintain hold with a lower target price (TP) of 62 sen: Sapura Energy Bhd’s first quarter of financial year 2019 (1QFY19) core net losses of RM165.7 million came below expectations on weaker-than-expected engineering and construction (E&C) contribution. While its order book and tender book remained flattish quarter-on-quarter (q-o-q) at RM16.7 billion and US$13 billion (RM52.
PMOIF PMO PMOIY
KUALA LUMPUR (June 29): Based on corporate announcements and news flow today, stocks in focus for Monday (July 2) may include the following: Malaysia Airports Holdings Bhd, Sapura Energy Bhd, MBM Resources Bhd, Parkson Holdings Bhd and Green Packet Bhd.
O9E SPXCF PMOIF 0082 PMO 5983 5014 S68 5657 SPXCY MYPRY BSMAF PMOIY 1818
KUALA LUMPUR (June 29): Sapura Energy Bhd's unit Sapura Exploration and Production (Sapura E&P) and its joint venture consortium partners, DEA Deutsche Erdoel Mexico and Premier Oil, have signed a production sharing contract (PSC) for Block 30 with Comision Nacional De Hidrocarburos of Mexico (CNH).
PMOIF PMO PMOIY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET